The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2007Understanding the Molecular and Functional Changes of CB1/D2/A2A Receptor Complexes in the Hemi-parkinsonian Pre-clinical Model
Objective/Rationale:
Future therapies in Parkinson’s disease (PD) may derive from the existence of intramembrane heteromeric receptor complexes containing the dopamine D2 receptor. The ability of... -
Clinical Intervention Awards, 2007The PARKFIT Study: Effectiveness of an Active Lifestyle Promotion Program for Patients with Parkinson’s disease
Objective/Rationale:
Parkinson's patients are inclined toward a sedentary lifestyle. This is due to a combination of both physical handicaps (e.g. walking difficulties) and mential impairments (e.g... -
Research Grant, 2010Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls
Objective/Rationale:
Parkinson’s disease (PD) is a common neurodegenerative disease that leads to progressive motor impairment as well as autonomic and cognitive disturbances. The cause of most of... -
Rapid Response Innovation Awards, 2014Disease-modifying Potential of Nortriptyline in Parkinson’s Disease
Objective/Rationale:
Aggregation of the protein alpha-synuclein is toxic to dopamine neurons. Therefore, a compound that reduces or clears this protein could be a viable therapeutic option... -
Defining Cognitive Phenotypes of Parkinson’s Disease, 2011Predicting Cognitive Profiles in Parkinson's Disease: A Multimodal Approach
Objective/Rationale:
Our proposal aims to determine the optimum combination of techniques to detect rate of cognitive decline in people with newly diagnosed Parkinson’s disease (PD). We will apply... -
Biomarkers, 2009Development of an alpha6*-Selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson's Disease Biomarker
Objective/Rationale:
The availability of a selective PET radiotracer for the drug target is critical for determining receptor occupancy in humans. NNR subtypes containing the alpha? subunit have been...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.